The advent of new HCV drugs has generated widespread economic concerns, particularly within the Italian setting, characterized by continuous linear cuts and spending review actions. The overall trade-off between investments and savings needs an in depth analysis.
from Gastroenterology via xlomafota13 on Inoreader http://ift.tt/29Zol74
via IFTTT
from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2agXvX5
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου